Literature DB >> 8280662

Second-line M-VAC therapy in patients previously treated with the M-VAC regimen for metastatic urothelial cancer.

J Kattan, S Culine, C Théodore, J P Droz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8280662     DOI： 10.1093/oxfordjournals.annonc.a058668

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

1.  Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma.

Authors:  Mark Warren; Michael Kolinsky; Christina M Canil; Piotr Czaykowski; Srikala S Sridhar; Peter C Black; Christopher M Booth; Wassim Kassouf; Libni Eapen; Som D Mukherjee; Normand Blais; Bernhard J Eigl; Eric Winquist; Naveen S Basappa; Scott A North
Journal:  Can Urol Assoc J       Date:  2019-04-26       Impact factor: 1.862

Review 2.  The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG).

Authors:  Albert Font; Raquel Luque; José Carlos Villa; Montse Domenech; Sergio Vázquez; Enrique Gallardo; Juan Antonio Virizuela; Carmen Beato; Rafael Morales-Barrera; Antoni Gelabert; Sonia Maciá; Javier Puente; Gustavo Rubio; Xavier Maldonado; Begoña Perez-Valderrama; Alvaro Pinto; Ovidio Fernández Calvo; Enrique Grande; Javier Garde-Noguera; Eva Fernández-Parra; José Ángel Arranz
Journal:  Target Oncol       Date:  2019-02       Impact factor: 4.493

Review 3.  Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer.

Authors:  Ahmet Murat Aydin; Solomon L Woldu; Ryan C Hutchinson; Martin Boegemann; Aditya Bagrodia; Yair Lotan; Vitaly Margulis; Laura-Maria Krabbe
Journal:  Onco Targets Ther       Date:  2017-03-09       Impact factor: 4.147
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.